• Policy
• Companies with superior CP ratings get reduced fines
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am

• Policy
• ‘A multifaceted approach to reimburse high-priced drugs'
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am

• Policy
• 1st KOR trial of 'STX-721' to treat EGFR mutant NSCLC begins
• by Lee, Hye-Kyung Mar 11, 2024 05:55am

• Policy
• Fasenra's reimb application passes DREC review
• by Lee, Tak-Sun Mar 11, 2024 05:55am

• Policy
• Pfizer starts trial for its RSV drug sisunatovir on adults
• by Lee, Hye-Kyung Mar 8, 2024 05:19am

• Policy
• Pharmas impacted by ‘minoxidil’ bioequivalence test result
• by Lee, Hye-Kyung Mar 8, 2024 05:18am

• Policy
• CSL Behring’s hemophilia B Tx Idelvion reattempts reimb
• by Lee, Tak-Sun Mar 8, 2024 05:18am

• Policy
• 2yr use restriction lifted for Alimta+Keytruda combo reimb
• by Lee, Tak-Sun Mar 8, 2024 05:18am

• Policy
• DPK urges doctors to return to work
• by Lee, Jeong-Hwan Mar 7, 2024 07:16am

• Policy
• High-strength Ebixa generics start receiving approval again
• by Lee, Hye-Kyung Mar 7, 2024 07:16am